HEMLIBRA [package insert]. South San Francisco, CA: Genentech,
Data on file. Genentech, Inc.
FDA approves Genentech’s HEMLIBRA (emicizumab-kxwh) for hemophilia A
without factor VIII inhibitors. [press release]. South San Francisco,
CA: Genentech; October 4, 2018.
ClinicalTrials.gov. A study to evaluate the efficacy, safety, and
pharmacokinetics of prophylactic emicizumab versus no prophylaxis in
hemophilia A participants with inhibitors (HAVEN 1). NCT02622321.
https://clinicaltrials.gov/ct2/show/NCT02622321. Accessed August 1,
ClinicalTrials.gov. A study of emicizumab administered subcutaneously
(SC) in pediatric participants with hemophilia A and factor VIII
(FVIII) inhibitors (HAVEN 2). NCT02795767.
https://clinicaltrials.gov/ct2/show/NCT02795767. Accessed August 1,
ClinicalTrials.gov. A clinical trial to evaluate prophylactic
emicizumab versus no prophylaxis in hemophilia A participants without
inhibitors (HAVEN 3). NCT02847637.
https://clinicaltrials.gov/ct2/show/NCT02847637. Accessed August 1,
ClinicalTrials.gov. A study to evaluate the efficacy, safety,
pharmacokinetics, and pharmacodynamics of emicizumab given every 4
weeks in participants with hemophilia A (HAVEN 4). NCT03020160.
https://clinicaltrials.gov/ct2/show/NCT03020160. Accessed August 1,
Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic
cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa,
emicizumab, depends on its ability to bridge the antigens. Thromb
Young G, Liesner R, Sidonio R Jr, et al. Emicizumab prophylaxis
provides flexible and effective bleed control in children with
hemophilia A with inhibitors: results from the HAVEN 2 study.
Presented at: ASH 60th Annual Meeting of the American Society of
Hematology; December 1–4, 2018; San Diego, CA.
Callaghan M, Negrier C, Paz-Priel I, et al. Emicizumab treatment is
efficacious and well tolerated long term in persons with haemophilia
(PwHA) with or without FVIII inhibitors: pooled data from four HAVEN
studies. Slide deck presented at: ISTH 2019 Annual Meeting; July 9,
2019; Melbourne, AU.
Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in
hemophilia A with inhibitors. N Engl J Med.
Di Minno A, Spadarella G, Nardone A, et al. Attempting to remedy
sub-optimal medication adherence in haemophilia: the rationale for
repeated ultrasound visualisations of the patient’s joint status.
Blood Rev. 2019;33:106-119.
Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds
in haemophilia patients with inhibitors to factor VIII/IX. J Clin
Schrijvers LH, Schuurmans MJ, Fischer K. Promoting self-management
and adherence during prophylaxis: evidence-based recommendations for
haemophilia professionals. Haemophilia.
Manco-Johnson MM, Abshire TC, Shapiro AD, et al. Prophylaxis versus
episodic treatment to prevent joint disease in boys with severe
hemophilia. N Engl J Med. 2007;357(6):535-544.
National Hemophilia Foundation. Recommendation on the use and
management of emicizumab-kxwh (HEMLIBRA®) for hemophilia A
with and without inhibitors. December 6, 2018; New York, NY.
Young G, Liesner R, Chang TY, et al. A multicenter, open-label, phase
3 study of emicizumab prophylaxis in children with hemophilia A with
inhibitors. Blood. 2019;2019001869. doi:
Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study
of emicizumab given every 2 or 4 weeks in children with severe
haemophilia A without inhibitors. Haemophilia. 2019;25:979-987.
Kruse-Jarres R, Callaghan MU, Croteau SE, et al. Surgical experience
in two multicenter, open-label phase 3 studies of emicizumab in
persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2)
[abstract]. Presented at: 59th Annual Meeting of the American Society
of Hematology; December 9–12, 2017; Atlanta, GA.
Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis
in patients who have hemophilia A without inhibitors. N Engl J
National Hemophilia Foundation. MASAC update on the approval and
availability of the new treatment: Emicizumab (HEMLIBRA), for persons
with hemophilia A with inhibitors to factor VIII: Interim guidance on
acute bleed management and use of laboratory assays. November 24,
2017; New York, NY.
Sampei Z, Igawa T, Soeda T, et al. Identification and
multidimensional optimization of an asymmetric bispecific IgG antibody
mimicking the function of factor VIII cofactor activity. PLoS
Santagostino E, Parnes A, Dhalluin C, et al. Surgical procedures in
persons with haemophilia A (PwHA) without inhibitors receiving
emicizumab – experience from the HAVEN 3 study. Presented at: 12th
Annual Congress of the European Association of Haemophilia and Allied
Disorders (EAHAD); February 6–8, 2019; Prague, Czech Republic.